A phase 1b multicenter trial showed that the combination of Durvalumab and Osimertinib in the treatment of EGFR mutation-positive NSCLC patients can increase the incidence of interstitial lung disease (ILD)-related adverse events (AE) (35%) (41). Here, EGFR is linked to interstitial lung disease.